Biogen Inc
BIIB: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$995.00 | Crkr | Wfgxzqngf |
Biogen Shares Remain Undervalued Despite Our Lower $305 FVE
We're lowering our Biogen fair value estimate from $343 to $305, as despite the in-line performance for most of Biogen's portfolio in the second quarter, we're updating our model for recent news on generic and biosimilar competitive threats as well as the termination of three pipeline programs.